RSV/deltaNS2/delta1313/I1314L
Alternative Names: RSV ΔNS2/Δ1313/I1314L; RSV/ΔNS2/Δ1313/I1314LLatest Information Update: 28 Jul 2023
At a glance
- Originator National Institutes of Health (USA)
- Developer National Institute of Allergy and Infectious Diseases
- Class Respiratory syncytial virus vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Respiratory syncytial virus infections
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(In children, In infants, Prevention) in USA (Intranasal, Drops)
- 09 Dec 2021 The US Department Of Health And Human Services has patents pending worldwide for respiratory syncytial virus vaccine